Balaxi Pharmaceuticals (BALAXI) Q4 18/19 earnings summary

Executive summary

• International wholesale trading in pharmaceuticals and builders’ hardware began in Sep 2018; the YAP biscuit range was planned for launch in Angola in Q1 FY20.document-source3document-source37

• Within seven months of operations, accumulated losses of ₹148.54 lakh were eliminated and net worth reached ₹352.06 lakh.document-source3document-source37

Financial highlights

• FY19 revenue from operations was ₹1,359.54 lakh; other income ₹80.88 lakh; total income ₹1,440.42 lakh.document-source3document-source47

• EBITDA was ₹244.28 lakh, PBT ₹243.94 lakh and PAT ₹196.59 lakh; basic and diluted EPS were ₹6.47.document-source3document-source47

• Total assets rose to ₹610.78 lakh from ₹168.67 lakh; net worth was ₹352.06 lakh.document-source37document-source46

Outlook and guidance

• FY20 outlook called for maintaining the international trading run rate and pursuing growth through additional pharmaceutical and builders’ hardware products.document-source37

• More than 30 formulations had entered export markets after year-end; plans included expanding YAP biscuit SKUs and adding food products, following encouraging initial response.document-source37